CyclocurcuminCAS# 153127-42-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 153127-42-5 | SDF | Download SDF |
| PubChem ID | 69879809 | Appearance | Powder |
| Formula | C21H20O6 | M.Wt | 368.4 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-(4-hydroxy-3-methoxyphenyl)-6-[(~{E})-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-2,3-dihydropyran-4-one | ||
| SMILES | COC1=C(C=CC(=C1)C=CC2=CC(=O)CC(O2)C3=CC(=C(C=C3)O)OC)O | ||
| Standard InChIKey | IZLBLUIBVMGMIY-ZZXKWVIFSA-N | ||
| Standard InChI | InChI=1S/C21H20O6/c1-25-20-9-13(4-7-17(20)23)3-6-16-11-15(22)12-19(27-16)14-5-8-18(24)21(10-14)26-2/h3-11,19,23-24H,12H2,1-2H3/b6-3+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Grossamide K exerts a particularly strong anti-melanogenic activity on the cells without high cell toxicity. |
Cyclocurcumin Dilution Calculator
Cyclocurcumin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7144 mL | 13.5722 mL | 27.1444 mL | 54.2888 mL | 67.861 mL |
| 5 mM | 0.5429 mL | 2.7144 mL | 5.4289 mL | 10.8578 mL | 13.5722 mL |
| 10 mM | 0.2714 mL | 1.3572 mL | 2.7144 mL | 5.4289 mL | 6.7861 mL |
| 50 mM | 0.0543 mL | 0.2714 mL | 0.5429 mL | 1.0858 mL | 1.3572 mL |
| 100 mM | 0.0271 mL | 0.1357 mL | 0.2714 mL | 0.5429 mL | 0.6786 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Daidzein-4',7-diglucoside
Catalog No.:BCN8135
CAS No.:53681-67-7
- Quercetagetin
Catalog No.:BCN8729
CAS No.:90-18-6
- Osmundacetone
Catalog No.:BCN8739
CAS No.:123694-03-1
- 1-Methyl-2,8-dihydroxy-3-carboxy-9,10-anthraquinone
Catalog No.:BCN8727
CAS No.:1401414-53-6
- Quercetin 3-O-(6''-galloyl)-beta-D-galactopyranoside
Catalog No.:BCN6381
CAS No.:53171-28-1
- Physalin O
Catalog No.:BCN8710
CAS No.:120849-18-5
- N-(3-Methoxybenzyl)(9Z,12Z,15Z)-octadeca-9,12,15-trienamide
Catalog No.:BCN6439
CAS No.:383715-23-9
- Rhombifoline
Catalog No.:BCN6367
CAS No.:529-78-2
- Macrophylloside D
Catalog No.:BCN6366
CAS No.:179457-69-3
- cis-1-o-Caffeoylquinic acid
Catalog No.:BCN6390
CAS No.:1627537-95-4
- Soyasapogenol D
Catalog No.:BCN6370
CAS No.:65892-76-4
- 4-[4-[[6-O-[(2E)-3-(4-Hydroxyphenyl)-1-oxo-2-propen-1-yl]-2-O-(3,4,5-trihydroxybenzoyl)-beta-D-glucopyranosyl]oxy]phenyl]-2-butanone
Catalog No.:BCN6359
CAS No.:105274-16-6
- Caraganaphenol A
Catalog No.:BCN8731
CAS No.:174916-31-5
- 8-Hydroxypinoresinol diglucoside
Catalog No.:BCN6368
CAS No.:112747-99-6
- (-)-Epiafzelechin 3-O-gallate
Catalog No.:BCN8740
CAS No.:108907-43-3
- Steviol-19-O-Glucoside
Catalog No.:BCN6373
CAS No.:1185737-16-9
- Scutellarein-7-O-glucoside
Catalog No.:BCN8099
CAS No.:26046-94-6
- Quercetin 3-O-(6''-galloyl)-beta-D-glucopyranoside
Catalog No.:BCN8742
CAS No.:56316-75-7
- (R)-alpha-methyltryptamine
Catalog No.:BCN8160
CAS No.:7795-52-0
- 2''-O-acetylsaikosaponin A
Catalog No.:BCN8736
CAS No.:102934-42-9
- Trillikamtoside Q
Catalog No.:BCN8195
CAS No.:2098642-70-5
- Xanthoangelol
Catalog No.:BCN8741
CAS No.:62949-76-2
- Arecaidine
Catalog No.:BCN8282
CAS No.:499-04-7
- Isosilybin B
Catalog No.:BCN6764
CAS No.:142796-22-3
Cyclocurcumin, a curcumin derivative, exhibits immune-modulating ability and is a potential compound for the treatment of rheumatoid arthritis as predicted by the MM-PBSA method.[Pubmed:28339004]
Int J Mol Med. 2017 May;39(5):1164-1172.
The control and treatment of rheumatoid arthritis is a challenge in today's world. Therefore, the pursuit of natural disease-modifying antirheumatic drugs (DMRDs) remains a top priority in rheumatology. The present study focused on curcumin and its derivatives in the search for new DMRDs. We focused on prominent p38 mitogen-activated protein (MAP) kinase p38alpha which is a prime regulator of tumor necrosis factor-alpha (TNF-alpha), a key mediator of rheumatoid arthritis. In the present study, we used the X-ray crystallographic structure of p38alpha for molecular docking simulations and molecular dynamic simulations to study the binding modes of curcumin and its derivatives with the active site of p38alpha. The ATP-binding domain was used for evaluating curcumin and its derivatives. Molecular docking simulation results were used to select 4 out of 8 compounds. These 4 compounds were simulated using GROMACS molecular simulation platform; the results generated were subjected to molecular mechanics-Poisson Boltzmann surface area (MM-PBSA) calculations. The results showed Cyclocurcumin as a potential natural compound for development of a potent DMRD. These data were further supported by inhibition of TNF-alpha release from lipopolysaccharide (LPS)-stimulated human macrophages following Cyclocurcumin treatment.
Cyclocurcumin, an Antivasoconstrictive Constituent of Curcuma longa (Turmeric).[Pubmed:28068085]
J Nat Prod. 2017 Jan 27;80(1):196-200.
Despite the increasing attention on the therapeutic potential of Curcuma longa (turmeric), the biological activities of curcuminoids other than curcumin are not well understood. Here, we investigated antivasoconstrictive activities of C. longa extract and its ingredients using freshly isolated rat aortic rings. C. longa extract significantly suppressed agonist-stimulated vasoconstriction, and Cyclocurcumin was found to be the most potent (IC50 against phenylephrine-induced vasoconstriction: 14.9 +/- 1.0 muM) among the 10 tested ingredients including four curcuminoids. Cyclocurcumin significantly inhibited contraction of vascular smooth muscle, which was mediated by the suppression of myosin-light-chain phosphorylation and calcium influx via the L-type calcium channel. The inhibitory effect of Cyclocurcumin was observed to be reversible and without cytotoxicity. Taken together, we demonstrated that Cyclocurcumin, a bioactive ingredient in C. longa, may have a therapeutic potential as a novel antivasoconstrictive natural product.
Molecular docking studies of curcumin natural derivatives with DNA topoisomerase I and II-DNA complexes.[Pubmed:25118649]
Interdiscip Sci. 2014 Dec;6(4):285-91.
DNA topoisomerase I (topo I) and II (topo II) are essential enzymes that solve the topological problems of DNA by allowing DNA strands or double helices to pass through each other during cellular processes such as replication, transcription, recombination, and chromatin remodeling. Their critical roles make topoisomerases an attractive drug target against cancer. The present molecular docking study provides insights into the inhibition of topo I and II by curcumin natural derivatives. The binding modes suggested that curcumin natural derivatives docked at the site of DNA cleavage parallel to the axis of DNA base pairing. Cyclocurcumin and curcumin sulphate were predicted to be the most potent inhibitors amongst all the curcumin natural derivatives docked. The binding modes of Cyclocurcumin and curcumin sulphate were similar to known inhibitors of topo I and II. Residues like Arg364, Asn722 and base A113 (when docked to topo I-DNA complex) and residues Asp479, Gln778 and base T9 (when docked to topo II-DNA complex) seem to play important role in the binding of curcumin natural derivatives at the site of DNA cleavage.
